London specialist clinic Santis Health has received a 2026 Global Recognition Award for combining robotic prostatectomy, real-time pathology and multidisciplinary planning in prostate cancer care.

Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to ...

Santis Health advances prostate cancer treatment through robotic surgery, intraoperative pathology, and multidisciplinary ...

Diagnosed in December 2022, medical professional Shailesh Pathak opted for non-surgical treatment over prostate removal due ...

Women with early-stage breast cancer could be spared multiple rounds of gruelling radiotherapy under a “breakthrough” cancer ...

A retrospective cohort study of 124 men with biopsy Gleason 6 prostate cancer found that elevated PSA density and perineural ...

Azerbaijani Foreign Minister Jeyhun Bayramov met with his Turkish counterpart, Hakan Fidan, in Ankara, the Azerbaijani ...

What’s New On Radiotherapy of Prostate Cancer in 2026? / OncoDaily RT, prostate cancer, prostate cancer radiotherapy, ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

Several studies presented at the 2026 European Society for Medical Oncology (ESMO) Congress explored treatment intensification and biomarker assessment across genitourinary (GU) cancers. Findings ...

Darolutamide plus ADT and radiotherapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone.

A prospective study of 24 men found that 18F-Flotufolastat PSMA PET MRI detected recurrent prostate cancer in 25 percent of ...